Nothing Special   »   [go: up one dir, main page]

MA33119B1 - Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase - Google Patents

Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase

Info

Publication number
MA33119B1
MA33119B1 MA34164A MA34164A MA33119B1 MA 33119 B1 MA33119 B1 MA 33119B1 MA 34164 A MA34164 A MA 34164A MA 34164 A MA34164 A MA 34164A MA 33119 B1 MA33119 B1 MA 33119B1
Authority
MA
Morocco
Prior art keywords
glucokinase
glucokinase inhibitors
benzofuranyl derivatives
benzofuranyl
derivatives
Prior art date
Application number
MA34164A
Other languages
Arabic (ar)
English (en)
Inventor
Anthony Lai Ling
Jeffrey Allen Pfefferkorn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42124287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33119(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA33119B1 publication Critical patent/MA33119B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (I) qui agissent comme activateurs de la glucokinase. L'invention concerne également des compositions pharmaceutiques comprenant ceux-ci ; et des procédés de traitement de maladies, de troubles, ou d'états pathologiques induits par la glucokinase.
MA34164A 2009-03-11 2010-03-04 Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase MA33119B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15909909P 2009-03-11 2009-03-11
PCT/IB2010/050943 WO2010103437A1 (fr) 2009-03-11 2010-03-04 Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase

Publications (1)

Publication Number Publication Date
MA33119B1 true MA33119B1 (fr) 2012-03-01

Family

ID=42124287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34164A MA33119B1 (fr) 2009-03-11 2010-03-04 Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase

Country Status (38)

Country Link
US (2) US8455496B2 (fr)
EP (2) EP2604604A1 (fr)
JP (1) JP5086480B2 (fr)
KR (1) KR101295937B1 (fr)
CN (1) CN102388038B (fr)
AP (1) AP3179A (fr)
AR (1) AR075729A1 (fr)
AU (1) AU2010222589B2 (fr)
BR (1) BRPI1013246B1 (fr)
CA (1) CA2754681C (fr)
CL (1) CL2011002185A1 (fr)
CO (1) CO6430427A2 (fr)
CR (1) CR20110467A (fr)
CU (1) CU24036B1 (fr)
DK (1) DK2406253T3 (fr)
DO (1) DOP2011000279A (fr)
EA (1) EA018894B1 (fr)
EC (1) ECSP11011306A (fr)
ES (1) ES2427279T3 (fr)
GE (1) GEP20156239B (fr)
HK (1) HK1164281A1 (fr)
HR (1) HRP20130661T1 (fr)
IL (1) IL214942A (fr)
MA (1) MA33119B1 (fr)
MY (1) MY151246A (fr)
NI (1) NI201100166A (fr)
NZ (1) NZ595024A (fr)
PE (1) PE20120668A1 (fr)
PL (1) PL2406253T3 (fr)
PT (1) PT2406253E (fr)
RS (1) RS52903B (fr)
SI (1) SI2406253T1 (fr)
TN (1) TN2011000454A1 (fr)
TW (1) TWI383981B (fr)
UA (1) UA99882C2 (fr)
UY (1) UY32480A (fr)
WO (1) WO2010103437A1 (fr)
ZA (1) ZA201106632B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557895T3 (es) 2010-03-19 2016-01-29 Pfizer Inc Derivados de 2,3-dihidro-1H-inden-1-il-2,7-diazaespiro[3.6]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina
SG189883A1 (en) 2010-10-29 2013-06-28 Pfizer N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
NZ616156A (en) 2011-04-22 2014-08-29 Pfizer Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors
JP2014520879A (ja) 2011-07-15 2014-08-25 ファイザー・インク Ｇｐｒ１１９調節因子
EP2734503B1 (fr) 2011-07-22 2015-09-16 Pfizer Inc. Modulateurs des récepteurs de quinolinylglucagon
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
EP2776405A1 (fr) 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
WO2013150416A1 (fr) 2012-04-06 2013-10-10 Pfizer Inc. Inhibiteurs de diacylglycérol acyltransférase 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
EP2897964A1 (fr) 2012-09-20 2015-07-29 Pfizer Inc. Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
JP2016502978A (ja) 2012-12-11 2016-02-01 ファイザー・インク ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
EP2956458B1 (fr) 2013-02-13 2017-08-09 Pfizer Inc Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
CA2942759C (fr) 2014-03-17 2018-01-09 Pfizer Inc. Inhibiteurs de diacylglycerol acyltransferase pour le traitement de troubles metaboliques ou analogues
PT3536685T (pt) 2014-04-04 2022-03-28 Pfizer Compostos bicíclicos de heteroarilo ou arilo fusionados e a sua utilização como inibidores de irak4
EA030085B1 (ru) 2014-04-10 2018-06-29 Пфайзер Инк. 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
CN104387348A (zh) * 2014-10-27 2015-03-04 湖南华腾制药有限公司 一种苯并呋喃衍生物的制备方法
WO2016092413A1 (fr) 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
EP3237401B1 (fr) 2014-12-22 2019-03-06 Pfizer Inc Antagonistes de récepteur ep3 de prostaglandine
KR101999463B1 (ko) 2015-03-03 2019-10-01 사니오나 에이/에스 테소펜신, 베타 차단제 복합 제형
JP2018515480A (ja) 2015-05-05 2018-06-14 ファイザー・インク ２−チオピリミジノン
US10308615B2 (en) 2015-05-29 2019-06-04 Pfizer Inc. Heterocyclic compounds as inhibitors of Vanin-1 enzyme
TN2017000485A1 (en) 2015-06-17 2019-04-12 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2016203335A1 (fr) 2015-06-18 2016-12-22 Pfizer Inc. Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
JP2018527337A (ja) 2015-08-13 2018-09-20 ファイザー・インク 二環式縮合ヘテロアリールまたはアリール化合物
EP3858825A1 (fr) 2015-08-27 2021-08-04 Pfizer Inc. Composés hétéroaryles bicycliques condensés en tant que modulateurs d'irak 4
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
WO2017051294A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace
EP3353182A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc Dérivés de tétrahydropyrano[3,4-d][1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
WO2017051276A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
AU2016380920B2 (en) 2015-12-29 2019-10-31 Pfizer Inc. Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
KR20190026902A (ko) 2016-07-14 2019-03-13 화이자 인코포레이티드 바닌-1 효소의 억제제로서의 신규 피리미딘 카르복스아미드
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
WO2019133445A1 (fr) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
AU2019278013A1 (en) * 2018-05-31 2021-01-21 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
WO2020044266A1 (fr) 2018-08-31 2020-03-05 Pfizer Inc. Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées
US20210338776A1 (en) * 2018-09-06 2021-11-04 Yale University Treatments against mosquito-borne viruses based on mosquito salivary gland proteins
WO2020102575A1 (fr) 2018-11-16 2020-05-22 Inception Ibd, Inc. Aminothiazoles hétérocycliques et leurs utilisations
CN113874019A (zh) 2019-05-20 2021-12-31 辉瑞大药厂 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
JP7498199B2 (ja) 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
AU2021216324A1 (en) 2020-02-07 2022-08-25 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
AU2021289169B2 (en) 2020-06-09 2024-01-04 Pfizer Inc. Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
WO2023026180A1 (fr) 2021-08-26 2023-03-02 Pfizer Inc. Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide
MX2024006739A (es) 2021-12-01 2024-06-19 Pfizer Derivados de acido 3-fenil-1-benzotiofeno-2-carboxilico como inhibidores de alfa cetoacido deshidrogenasa quinasa de cadena ramificada para el tratamiento de diabetes, enfermedad renal, esteatohepatitis no alcoholica (nash) e insuficiencia cardiaca.
EP4444708A1 (fr) 2021-12-06 2024-10-16 Pfizer Inc. Antagonistes du récepteur 4 de la mélanocortine et leurs utilisations
WO2023169456A1 (fr) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Agonistes hétérocycliques de glp-1
WO2023198140A1 (fr) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
WO2024075051A1 (fr) 2022-10-07 2024-04-11 Pfizer Inc. Inhibiteurs et/ou agents de dégradation de hsd17b13
WO2024084360A1 (fr) 2022-10-18 2024-04-25 Pfizer Inc. Modificateurs de la proteine 3 contenant le domaine phospholipase de type patatine (pnpla3)
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
WO2024125602A1 (fr) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Sels et formes solides d'un composé ayant une activité agoniste de glp-1
WO2024127297A1 (fr) 2022-12-16 2024-06-20 Pfizer Inc. Inhibiteurs et/ou agents de dégradation contenant du 3-fluoro-4-hydroxybenzmide et leurs utilisations
WO2024214038A1 (fr) 2023-04-14 2024-10-17 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
WO1994001415A1 (fr) 1992-07-03 1994-01-20 Kumiai Chemical Industry Co., Ltd. Derive heterocyclique condense et desherbant
KR100381584B1 (ko) 1994-07-22 2003-08-21 알타나 파마 아게 디히드로벤조푸란
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
WO1996011925A1 (fr) 1994-10-13 1996-04-25 Pfizer Inc. Composes de benzopyranne et composes benzo-fusionnes, leur preparation et leur utilisation comme antagonistes du leucotriene b4' (ltb4)
WO1996011920A1 (fr) 1994-10-13 1996-04-25 Pfizer Inc. Composes de benzopyranne et composes benzo-fusionnes, leur preparation et leur utilisation comme antagonistes de leucotriene b4 (ltb4)
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
EP0901482B1 (fr) 1996-05-20 2003-05-02 Darwin Discovery Limited Carboxamides de benzofurane et leurs utilisations therapeutiques
JP4309475B2 (ja) 1996-08-19 2009-08-05 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンゾフラン―４―カルボキサミド
EP1054884A1 (fr) 1998-02-09 2000-11-29 Darwin Discovery Limited Benzofuran-4-carboxamides et leur utilisation therapeutique
CA2359113A1 (fr) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Composes inhibant l'adhesion aux leucocytes a mediation assuree par vla-4
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2002020463A2 (fr) 2000-09-05 2002-03-14 Tularik Inc. Modulateurs fxr
US6670380B2 (en) 2000-11-20 2003-12-30 Bristol-Myers Squibb Co. Pyridone inhibitors of fatty acid binding protein and method
AU2002221902B2 (en) 2000-12-06 2006-11-23 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
CZ20032325A3 (cs) 2001-02-28 2004-02-18 Erck & Co., Inc. Acylované piperidinové deriváty
EP1403255A4 (fr) 2001-06-12 2005-04-06 Sumitomo Pharma Inhibiteurs de rho kinase
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CA2464214C (fr) 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees
KR100705519B1 (ko) 2002-02-14 2007-04-10 파마시아 코포레이션 Ｐ３８ ｍａｐ 키나제의 조절제로서의 치환된 피리디논
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
JP2005538047A (ja) 2002-05-03 2005-12-15 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ボンベシンアンタゴニスト
JP4287816B2 (ja) 2002-06-13 2009-07-01 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ピラゾールカルボキサミド殺虫剤
JP4302967B2 (ja) * 2002-11-18 2009-07-29 パイオニア株式会社 楽曲検索方法、楽曲検索装置及び楽曲検索プログラム
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (fr) 2002-12-23 2004-06-30 Jerini AG Utilisation de nitriles en tant qu'inhibiteurs de rotamase
EP1594863A1 (fr) 2003-02-11 2005-11-16 Prosidion Limited Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
JP4400563B2 (ja) 2003-02-13 2010-01-20 萬有製薬株式会社 新規２−ピリジンカルボキサミド誘導体
CN100378094C (zh) * 2003-02-13 2008-04-02 万有制药株式会社 2-吡啶甲酰胺衍生物
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
WO2004076420A1 (fr) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. Derives d'heteroarylcarbamoylbenzene
WO2005009993A1 (fr) 2003-07-15 2005-02-03 Smithkline Beecham Corporation Nouveaux composes
JP4727578B2 (ja) 2003-08-01 2011-07-20 中外製薬株式会社 マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用な複素環式化合物
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
US7750020B2 (en) 2004-04-02 2010-07-06 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
JP4719745B2 (ja) 2004-07-29 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャンネル阻害剤
US20060058525A1 (en) 2004-09-01 2006-03-16 Rajinder Singh Synthesis of 2,4-pyrimidinediamine compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
BRPI0516381A (pt) 2004-12-21 2008-09-02 Hoffmann La Roche derivados de cromano e seu uso como ligandos de receptor de 5-ht
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JP2008534664A (ja) 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
RU2008112184A (ru) 2005-08-31 2009-10-10 Астеллас Фарма Инк. (Jp) Производное тиазола
JP2009013065A (ja) * 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
EP1951680A4 (fr) 2005-11-15 2011-08-10 Astrazeneca Ab Nouveaux derives de 2-aminopyrimidinone et leur utilisation
EP2001875A2 (fr) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Activateurs de la glucokinase
EP1999135A2 (fr) 2006-03-30 2008-12-10 Takeda San Diego, Inc. Inhibiteurs de kinase
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
PL2463283T3 (pl) * 2006-04-20 2014-10-31 Pfizer Prod Inc Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę
EP2091947A2 (fr) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Activateurs de glucokinase
JP2010138073A (ja) 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
JP2010529109A (ja) 2007-06-08 2010-08-26 アドビナス セラピュティックス プライベート リミテッド グルコキナーゼ活性化因子としてのピロール−２−カルボキサミド誘導体、そのプロセス及び薬学的応用
CA2748587A1 (fr) 2009-01-20 2010-07-29 Pfizer Inc. Pyrazinone amides substitues

Also Published As

Publication number Publication date
US8455496B2 (en) 2013-06-04
ES2427279T3 (es) 2013-10-29
AP2011005882A0 (en) 2011-10-31
PE20120668A1 (es) 2012-06-01
TW201036961A (en) 2010-10-16
IL214942A0 (en) 2011-11-30
AU2010222589A1 (en) 2011-09-22
EA201190158A1 (ru) 2012-04-30
NI201100166A (es) 2012-01-23
CU24036B1 (es) 2014-10-30
PL2406253T3 (pl) 2013-10-31
HK1164281A1 (en) 2012-09-21
CU20110168A7 (es) 2012-02-15
CA2754681A1 (fr) 2010-09-16
KR101295937B1 (ko) 2013-08-14
WO2010103437A1 (fr) 2010-09-16
CO6430427A2 (es) 2012-04-30
US8735396B2 (en) 2014-05-27
PT2406253E (pt) 2013-09-11
ZA201106632B (en) 2012-05-30
BRPI1013246A2 (pt) 2016-04-05
US20130252973A1 (en) 2013-09-26
EA018894B1 (ru) 2013-11-29
NZ595024A (en) 2013-01-25
SI2406253T1 (sl) 2013-09-30
CL2011002185A1 (es) 2012-02-03
US20100234285A1 (en) 2010-09-16
CN102388038A (zh) 2012-03-21
CR20110467A (es) 2011-10-07
UY32480A (es) 2010-10-29
TN2011000454A1 (fr) 2013-03-27
AP3179A (en) 2015-03-31
EP2406253A1 (fr) 2012-01-18
AU2010222589B2 (en) 2012-08-16
EP2604604A1 (fr) 2013-06-19
MY151246A (en) 2014-04-30
GEP20156239B (en) 2015-01-26
DOP2011000279A (es) 2011-10-15
TWI383981B (zh) 2013-02-01
DK2406253T3 (da) 2013-08-12
KR20110123288A (ko) 2011-11-14
RS52903B (en) 2014-02-28
JP5086480B2 (ja) 2012-11-28
HRP20130661T1 (en) 2013-08-31
CA2754681C (fr) 2014-01-07
CN102388038B (zh) 2014-04-23
IL214942A (en) 2015-10-29
AR075729A1 (es) 2011-04-20
EP2406253B1 (fr) 2013-07-03
ECSP11011306A (es) 2011-10-31
UA99882C2 (uk) 2012-10-10
JP2012520286A (ja) 2012-09-06
BRPI1013246B1 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MA32891B1 (fr) Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
MA33670B1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MX2009003981A (es) Agentes moduladores del receptor de calcio.
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone